Functional relationship between high mobility group A1 (HMGA1) protein and insulin-like growth factor-binding protein 3 (IGFBP-3) in human chondrocytes

Giorgio Gasparini¹, Marco De Gori¹, Francesco Paonessa², Eusebio Chiefari³, Antonio Brunetti³ and Olimpio Galasso¹*

Abstract

Introduction: Insulin-like growth factor I (IGF-I) regulates articular cartilage homeostasis. During osteoarthritis (OA), the anabolic responses of chondrocytes to IGF-I are likely to be prevented by the enhanced production of IGF-binding proteins (IGFBPs), especially IGFBP-3. The aim of this study is to evaluate whether the architectural transcription factor high mobility group A1 (HMGA1) influences IGFBP-3 overexpression in vitro, in cultured chondrocytic cell lines, and ex vivo, in human osteoarthritic cartilage compared to healthy human cartilage controls.

Methods: Quantitative real-time reverse transcription-PCR (qRT-PCR) was performed to assess the relative transcript levels of HMGA1 and IGFBP-3 in vitro, in the human chondrocytic cell lines T/C-28a4 and C-28/I2. An electrophoretic mobility shift assay (EMSA), chromatin immunoprecipitation (ChIP) and transient transfection assays were performed to investigate the HMGA1-IGFBP-3 gene interaction. Samples of articular cartilage were harvested from osteoarthritic patients and controls and analyzed by qRT-PCR for HMGA1 and IGFBP-3 mRNA levels.

Results: A parallelism between HMGA1 protein levels and IGFBP-3 gene expression has been observed in T/C-28a4 and C-28/I2 cells. The interaction of HMGA1 with the IGFBP-3 gene promoter has been demonstrated by EMSA and ChIP. In transient transfections, IGFBP-3 promoter activity increased in cells overexpressing HMGA1 and decreased in cells pretreated with siRNA detected against HMGA1. IGFBP-3 mRNA expression was higher in cartilage from patients with OA, where the increased expression of IGFBP-3 closely paralleled the increased expression of HMGA1 mRNA.

Conclusions: Our observations indicate that increased HMGA1 expression in human chondrocytes is associated with increased expression of IGFBP-3. It is tempting to speculate that, through the regulation of IGFBP3 expression, HMGA1 may act as a pathogenetic factor for OA.

Introduction

The high-mobility group A1 (HMGA1) protein is a small nuclear binding protein that participates in various fundamental cellular processes, including transcriptional regulation, embryogenesis, cell cycle regulation, transformation and differentiation, senescence, and DNA repair [1]. By interacting with AT-rich DNA binding sequences, HMGA1 is able to modify the structure of its target site and induce structural changes in the DNA to facilitate the progression of a wide range of DNA-dependent activities [2]. This interaction enables HMGA1 to recruit additional transcription factors and alter chromatin structure, leading to the formation of higher-order transcriptional complexes called enhanceosomes [3-5]. In concert with other factors, HMGA1 modulates gene expression and determines whether the associated genes are switched on or off [6].

* Correspondence: galasso@unicz.it
¹Department of Orthopedics, Magna Græcia University, V.le Europa, Catanzaro, 88100 Italy
Full list of author information is available at the end of the article

© 2012 Gasparini et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Through such a mechanism, the transcription of cyclo-
ogenase-2, insulin-like growth factor (IGF)-binding pro-
tein-1 (IGFBP-1), and the insulin receptor is regulated by
HMGA1 [4,5,7,8].
IGFBP-3 is a 38- to 43-kDa protein that regulates the bioavailability of IGF-I [9]. Detection of IGFBP-3 has been
reported in human chondrocytes in articular cartilage
[10,11]. Several cytokines, matrix metalloproteinases, and
growth factors [10,12-15] take part in the regulation of
articular cartilage homeostasis, and in developing articular
cartilage, IGF-I is an inducer of collagen and aggrecan
synthesis, representing an important factor in the mainte-
nance of the chondrocyte phenotype as well as cartilage
integrity and metabolism. During osteoarthritis (OA), nor-
mal or increased amounts of IGF-I are produced, but
osteoarthritic chondrocytes are hyporesponsive to IGF-I;
this property has been attributed to increased IGFBP levels
that may interfere with IGF-I functionality [16-18].
The role of HMGA1 in OA has not been previously
investigated. For the first time, we provide a comprehen-
sive analysis of the molecular mechanisms underlying the
activation of IGFBP-3 gene transcription in human chon-
drocytes. Using chromatin immunoprecipitation (ChIP)
combined with studies of DNA-protein interaction and
transient transfection assays in living cells, we demon-
strate that HMGA1 modulates the transcription of the
IGFBP-3 gene. Taken together, our findings provide a
mechanistic insight into the molecular processes that
influence IGFBP-3 gene expression in OA.

Materials and methods
Cells and protein extracts
HepG2 human hepatoma cells were cultured in RPMI
1640 medium supplemented with 10% fetal bovine
serum. Because they naturally express both IGFBP-3 and
HMGA1 protein species, these cells were used as a posi-
tive control model. T/C-28a4 and C-28/12 cells (a kind
gift from Mary B. Goldring, The Hospital for Special Sur-
gery, New York, NY, USA, and Elizaveta Kon, Rizzoli
Orthopedic Institute, Bologna, Italy) were cultured in
high-glucose (4.5 g/L) Dulbecco’s modified Eagle’s med-
ium supplemented with 10% fetal calf serum. Hepatoma,
T/C-28a4, and C-28/12 cell systems were supplemented
with glutamine (2 mM), penicillin (100 IU/mL), and
streptomycin (100 mg/mL) in a humidified atmosphere
containing 5% CO2 at 37°C. Cytoplasmic and nuclear
extracts were prepared as previously described [19], and
the final protein concentration in the extract was deter-
mained according to the Bradford method (Bio-Rad
Laboratories, Inc., Hercules, CA, USA).

Oligonucleotides and electrophoretic mobility shift assay
Human IGFBP-3 gene promoter sequences were ampli-
fied from genomic DNA by polymerase chain reaction
(PCR) by using the following specific primers: h1 for-
ward, 5′-ATACAGTAAATACGGAATCGCC-3′; h1 reverse, 5′-ACCGGCAAGCGAATGCTCCTT-3′; h2 forward,
5′-TGGGGATATAAACAGCCCAGC-3′; and h2 reverse,
5′-ATACAGCGCTCAGCATCTGTG-3′. Frag-
ments were end-labeled with [32P]dATP and used in an
electrophoretic mobility shift assay (EMSA) as pre-
viously described [19].

Chromatin immunoprecipitation
ChIP was performed as previously described [20] by using
HepG2 cells. Formaldehyde-fixed DNA-protein complexes
were immunoprecipitated with anti-HMGA1 antibody
[19]. The following primers were used to amplify the
region between -295 and -571 base pairs in the IGFBP-3
gene promoter: forward, 5′-TGGGGATATAAACAGCCC-
CAGC-3′ and reverse, 5′-GGTACCCCCAGTACCTCTCT-
3′. The PCR products were electrophoretically resolved on
a 1.5% agarose gel and visualized by ethidium bromide
staining.

Plasmids and transfections
A human IGFBP-3 reporter plasmid (pGL3-IGFBP-3 Luc)
was constructed by cloning the 1,876-base pair sequence
of the human IGFBP-3 promoter (-1804/+72) into the
pGL3 luciferase reporter vector (Promega Corporation,
Madison, WI, USA) by using the Nhe I and Bgl II sites.
The integrity of this construct was determined by DNA
sequencing. pGL3-IGFBP-3 Luc was transiently trans-
fected into cultured cells together with pcDNA3/HA-
HMGA1 (a generous gift from Guidalbeto Manfioletti,
University of Trieste, Trieste, Italy), pEVR2/Sp1 [4], and
pSG5-C/EBPβ [4] vectors in the absence or presence of
HMGA1 small interfering RNA (siRNA) (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA) by using the
Lipofectamine 2000 transfection reagent protocol (Invitro-
gen Life Technologies Corporation, Carlsbad, CA, USA).
Luc activity was assayed between 48 and 96 hours later as
previously described [21].

Tissue preparation
The study protocol was approved by the local ethics
committee, and the research was carried out in compli-
ance with the Declaration of Helsinki. Informed written
consent was obtained from all individuals. In total, 28
donors recruited at our outpatient clinic between January
2009 and January 2011 were grouped in two clusters.
The first cluster consisted of 21 patients (10 women and
11 men with a mean age of 67.7 ± 7.7 years) who had OA
(11 hip OA and 10 knee OA) and whose diagnosis was
based on established clinical, biochemical, and radiologi-
cal criteria [22,23]; all patients were subjected to total
joint replacement. A radiological classification of each
osteoarthritic joint was carried out according to the
Kellgren-Lawrence [24] or Ahlbäck [25] scales. X-rays were independently evaluated by two musculoskeletal radiologists, who were unaware of the clinical characteristics of the patients, and the same measurements were repeated twice on two separate days. Cohen’s kappa coefficients for interobserver and intraobserver reliability of scoring were 0.80 and 0.84, respectively. A consensus decision on the scores was reached in a final common readout, and a severe OA grade was noted in all patients (that is, five cases of grade III/IV hip OA, six cases of grade IV/IV hip OA, six cases of grade IV/V knee OA, and four cases of grade V/V knee OA). Patients with secondary OA or those who were previously subjected to intra-articular injections of corticosteroids, hyaluronic acid, or non-steroidal anti-inflammatory drugs were excluded from the study. The second cluster consisted of seven healthy donors (three women and four men with a mean age of 41.6 ± 10.7 years) with no OA or other diseases that may potentially alter the articular cartilage. Samples of articular cartilage were obtained as discarded surgical material in both clusters of patients. Specifically, cartilage was taken from the femoral head in patients with hip OA and from both femoral condyles and the tibial plateau in patients with knee OA. In the control group, the donor sites were the knee (three), hip (two), shoulder (one), and the proximal interphalangeal joint of the foot (one). All patients observed a pain medication-free interval 30 days prior to surgery. After the cartilage was removed from the joint, it was extensively washed with an isotonic saline solution to remove residual blood or synovial fluid. Specimens were excised from the superficial and deep layers of the articular cartilage by using disposable scalp knife blades, avoiding the calcified layer and the subchondral bone. Approximately 0.5 cm³ of cartilage was dissected from the rim of the ulcer present in all specimens from patients with OA, and an equal amount of tissue was taken far from the ulcer. This procedure of pooling together different samples of cartilage from the same joint overcomes, at least in part, the possible bias originating from the presence of non-homogenous osteoarthritic damage throughout the joint or the effect of a random choice of the tissue to be harvested. Samples were pooled, immediately immersed in liquid nitrogen, and stored at -80°C until analysis. Whole cartilage from healthy donors was similarly preserved.

RNA preparation and qRT-PCR
Total cellular RNA was extracted from T/C-28a4 and C-28/12 cultured cells by using the RNAqueous-4PCR Kit (Ambion, Austin, TX, USA). RNA isolation from cartilage samples was performed by using the TRI Reagent solution protocol (Ambion). The isolated RNA was subjected to Dnasel treatment, and cDNA was synthesized from 1 μg of total RNA. Both the yield of RNA and the 260/280 absorbance ratio were similar between samples obtained from osteoarthritic and healthy cartilage (data not shown). cDNA (10 ng) was used as a template in the quantitative real-time reverse transcription-PCR (qRT-PCR) reaction by using SYBR Green dye. Product accumulation was monitored with a Mastercycler ep Realplex (Eppendorf, Wesseling-Berzdorf, Germany) detection system. The mean cycle threshold (Ct) value was calculated from triplicate samples and used to determine the gene expression level. The sample ΔCt (SΔCt) value was calculated as the difference between the ribosomal protein S9 (RPS9) Ct and sample Ct values. The expression levels of type X collagen (ColX), HMGA1, and IGFBP-3 were expressed versus the control sample ΔCt (CΔCt) values. It has been previously described that ColX, the standard marker for chondrocyte hyperthrophy [26], overexpresses in human osteoarthritic cartilage with respect to healthy adult articular cartilage [13,27-29]. Fold differences with respect to the control were determined by using the formula R = 2 - (SΔCt - CΔCt), where R represents a relative quantification. Target and housekeeping genes were amplified by using the following primers: COLXA1 forward, 5'-ACAGGAATGCTGTGTCTGTATTTACT-3', COLXA1 reverse, 5'-CATTTGGAAGCTGGAGCACTACCCATGGTAC-3', HMGA1 forward, 5'-AGGACGACTGACCATGCGT-3'; HMGA1 reverse, 5'-TGATGGTGGGCTTGGGAAG-3'; IGFBP-3 forward, 5'-GGATGTGAGCACTATCCAG-3'; IGFBP-3 reverse, 5'-CAACATGTGGTGAAGGTTCC-3'; and RPS9 forward, 5'-CAGCTTGGTCCATTCCCTCAT-3' and RPS9 reverse, 5'-CTGCTGAGCTTTGATGAA-3'.

Statistical analysis
Student t test was used to assess the significance of the differences between values. The analysis of variance was used to evaluate the comparisons within the transient transfection assays. To calculate the power (1-β error probability; two-tailed) achieved by our statistical tests, we considered the actual sample size, the size of the observed effect, and the α value of 0.05. SPSS (version 17.0; SPSS Inc., Chicago, IL, USA) and G*Power (version 3.1; Institut für Experimentelle Psychologie, Heinrich Heine Universität, Düsseldorf, Germany) software were used for the database construction and the statistical analysis. A P value of less than 0.05 was considered significant.

Results
HMGA1 and IGFBP-3 expression in T/C-28a4 and C-28/12 cells
As measured by qRT-PCR, IGFBP-3 and HMGA1 mRNA expression was observed in both T/C-28a4 and C-28/12 cultured cell lines (Figure 1a). However, this expression was higher in C-28/12 cells, and this may be
Figure 1 IGFBP-3 and HMGA1 mRNA expression in chondrocytic cell lines. (a) A comparison of IGFBP-3 and HMGA1 mRNA abundance is shown in T/C-28a4 (black columns) and C-28/I2 (gray columns) cells following qRT-PCR of total RNA from three separate experiments. *P = 0.0016; **P = 0.0005. (b) IGFBP-3 and HMGA1 mRNA as measured by qRT-PCR from cultured C-28/I2 cells pretreated with small interfering RNA directed against HMGA1 (gray columns) or untreated (black columns). *P = 0.0046; **P = 0.0004. (c) qRT-PCR of IGFBP-3 and HMGA1 mRNA in T/C-28a4 cells transfected with a pcDNA3/HA-HMGA1 expression vector (gray columns) or untransfected (black columns). *P = 0.0039; **P = 0.0031. Each column indicates the mean value; the error bars indicate standard deviation. HMGA1, high-mobility group A1; IGFBP-3, insulin-like growth factor binding protein 3; qRT-PCR, quantitative real-time reverse transcription-polymerase chain reaction.
consistent with the fact that these cells resemble primary chondrocytes more closely than T/C-28a4 cells do [30]. IGFBP-3 mRNA abundance in both cell lines closely paralleled HMGA1 mRNA production, suggesting that HMGA1 may play a role in IGFBP-3 gene activation. To examine further the role of HMGA1 in this event, we carried out experiments in C-28/12 cells treated with siRNA directed against HMGA1. As shown in Figure 1b, a contextual significant decrease in both IGFBP-3 and HMGA1 mRNA levels was observed in C-28/12 cells following transfection with HMGA1 siRNA. Conversely, an increase in IGFBP-3 expression was observed in T/C-28a4 cells following transfection with a pcDNA3/HA-HMGA1 expression plasmid that induced HMGA1 overexpression (Figure 1c). Taken together, these results indicate that a parallelism exists between IGFBP-3 and HMGA1 mRNA expression in chondrocytic cell lines.

Physical interaction of HMGA1 with the IGFBP-3 promoter

A schematic representation of the promoter region of the human IGFBP-3 gene is shown in Figure 2. Consensus transcription factor-binding sites within this region were explored by searching the TRANSFAC database by using MatInspector [31]. Putative binding sites for HMGA1 were identified together with consensus sites for the CAAT-enhancer binding protein β (C/EBPβ) and the ubiquitously expressed transcription factor Sp1. We focused on HMGA1 cis-sites surrounding the first 900 base pairs upstream of the transcriptional start site, which are usually associated with a more intense promoter activity [4]. DNA-HMGA1 protein interaction was characterized in vitro by EMSA by using the sequence-specific radiolabeled fragments h1 and h2, which include HMGA1 cis-sites flanking the Sp1 and C/EBPβ DNA binding motifs. As shown in Figure 2, binding of a pure recombinant HMGA1 isoform to these probes produced a protein-DNA complex that was recognized by the anti-HMGA1-specific antibody and was supershifted to a slower-migrating form. No DNA-HMGA1 protein interaction was observed when a non-AT-rich sequence of the IGFBP-3 gene promoter was used as a probe. The interaction of HMGA1 with the IGFBP-3 gene promoter was further explored in this study by ChIP analysis by using HepG2 cells, which naturally express HMGA1. As shown in Figure 3, binding of endogenous HMGA1 occurred at the IGFBP-3 gene locus in intact HepG2 cells. However, when HMGA1 expression was perturbed in HepG2 cells treated with siRNA directed against HMGA1, the DNA binding ability of HMGA1 was significantly reduced. This finding indicates that HMGA1 binds directly to the IGFBP-3 gene promoter and suggests a molecular mechanism for HMGA1-based stimulation of IGFBP-3 gene expression.

HMGA1 is required for full activation of IGFBP-3 gene transcription

Considering the observation that a physical interaction occurs between HMGA1 and the human IGFBP-3 promoter, we next investigated the functional significance of this DNA-protein interaction. To this end, HepG2 cells were transiently transfected with a human IGFBP-3-Luc reporter plasmid in the presence or absence of expression vectors containing HMGA1, Sp1, or C/EBPβ. As shown
in Figure 4, IGFBP-3-Luc activity was enhanced in HepG2 cells overexpressing HMGA1. Induction of IGFBP-3-Luc activity markedly increased when both Sp1 and C/EBPβ were transfected simultaneously, implying that these nuclear factors function together to induce full IGFBP-3 gene transcription. Interestingly, the effect of Sp1 and C/EBPβ was blocked by treating cells with siRNA directed against HMGA1, confirming that HMGA1 plays a role in this process.

HMGA1 and IGFBP-3 mRNA expression in patients with osteoarthritis

Increased IGFBP-3 protein expression has been previously reported in the cartilage of patients with OA [32,33]. Considering the above findings, which indicate that a functional relationship between HMGA1 and IGFBP-3 does indeed exist, we carried out studies in osteoarthritic human cartilage. As shown in Figure 5, IGFBP-3 mRNA expression, as measured by qRT-PCR, was significantly higher in cartilage from patients with OA compared with cartilage from healthy donors. Interestingly, the increased expression of IGFBP-3 in these patients closely paralleled the increased levels of HMGA1 mRNA, and this supports the hypothesis that HMGA1 may be responsible for IGFBP-3 overexpression in chondrocytes from patients with OA. Power analyses showed that the statistical tests used to compare ColX, IGFBP-3, and HMGA1 mRNA expression between cartilage from patients with OA and healthy donors had 99% power to detect the observed differences.

Discussion

A key role for IGFBP-3 in modulating IGF-I bioavailability in human chondrocytes has been suggested previously [11,16-18,34]. However, the molecular mechanisms

Figure 3 ChIP of the IGFBP-3 gene promoter. HepG2 cells, either untreated (U) or treated (T) with small interfering RNA directed against HMGA1, were used for ChIP of the IGFBP-3 gene by using a polyclonal antibody against HMGA1. There were three separate experiments. ChIP, chromatin immunoprecipitation; HMGA1, high-mobility group A1; IGFBP-3, insulin-like growth factor binding protein 3.

Figure 4 Functional significance of HMGA1 for IGFBP-3 gene transcription. HepG2 cells were transfected with the pGL3-IGFBP-3 Luc reporter plasmid (1 μg) in the presence of the indicated effector vectors (0.5 μg each, black columns). Empty column indicates mock (no DNA). Functional analysis with small interfering RNA directed against HMGA1 (100 pmol) is shown in the gray column. Transcriptional activity of the IGFBP-3 promoter is shown as the ratio of Luc activity to Renilla activity (Luc/Ren). Columns indicate mean values; error bars denote standard deviation. There were three separate experiments. *P = 0.03; **P < 0.0001; ***P < 0.0001. C/EBPβ, CAAT-enhancer binding protein β; HMGA1, high-mobility group A1; IGFBP-3, insulin-like growth factor binding protein 3.
regulating expression in chondrocytes are still unknown. The possibility that HMGA1 plays a role in IGFBP-3 gene regulation is supported by the data in our present study, indicating that transactivation of the IGFBP-3 gene by the nuclear transcription factors Sp1 and C/EBPβ is dependent on HMGA1.

In our study, the functional link between HMGA1 and IGFBP-3 was initially evaluated by molecular biological techniques and gene expression analyses in both T/C-28a4 and C-28/I2 chondrocytic cultured cells, which are two in vitro cell models that are commonly used for studying articular cartilage pathophysiology [30]. Our results clearly indicate that HMGA1 positively modulates IGFBP-3 gene expression in both chondrocyte cell lines. This finding is in apparent contrast to previous observations indicating that downregulation of the IGFBP-3 gene by HMGA1 occurs in mouse C2C12 cells that stably overexpress HMGA1 [35]. An explanation for this apparent discrepancy could be that the sustained induced overexpression of HMGA1 in C2C12 cells may severely preclude IGFBP-3 expression by preventing myoblast differentiation. This possibility is supported by the fact that the expression of both myogenin and MyoD, two key players in muscle cell differentiation [36,37], is abolished in C2C12 cells constitutively expressing HMGA1. Furthermore, the cell specificity of HMGA1 action should be considered. In this respect, a differential role of HMGA1 as either an activator or an inhibitor of cellular biological processes has been documented [1]. The in vitro data in cultured chondrocytes were confirmed in articular cartilage samples from patients with OA. In agreement with previous studies [32,33], IGFBP-3 levels were increased in the cartilage of patients with OA, and a parallel increase in HMGA1 expression was detected simultaneously. To the best of our knowledge, this latter observation has not been reported before, and the increase in HMGA1 expression in these patients constitutes a novel finding in this study. We next observed an overexpression of type X collagen in osteoarthritic cartilage. However, caution should be exerted in interpreting this overexpression because conflicting results have been published for the expression of this collagen type in OA [26].

Autocrine IGFBP-3 production in intact cartilage has been reported [32]. Notably, the increase of IGFBP-3 during OA may affect the integrity of articular cartilage, diminishing the synthesis of matrix collagen and aggregan [9,13].

IGF-I functions in the stimulation and maintenance of the chondrocyte phenotype principally in immature cartilage [38]. Therefore, the reduced IGF-I bioavailability in OA might influence chondroptosis, thus creating cell-depleted cartilage [39-41]. An increase in IGFBP protein production has been widely demonstrated in both the articular cartilage and synovial fluid from patients with OA [16,34,42,43], and the increased amount of IGFBP-3 has been directly associated with the severity of the disease [32]. IGFBP-3 overexpression has been reported in the extracellular cartilage matrix and within both the cytoplasm and nuclear environment of osteoarthritic chondrocytes [11]. Cellular segregation of IGFBP-3 might also deliver IGF-independent signals [34]. Notably, the nuclear presence of IGFBP-3 in chondrocytes has been associated with the regulation of cell division and apoptosis [11]. However, the possibility that HMGA1 plays a direct role in chondroptosis cannot be excluded, and this possibility is consistent with data in the literature, indicating that apoptosis in non-neoplastic cells can be induced by HMGA1 [44]. Finally, a possible role for HMGA1 and IGFBP-3 in response to OA-induced hypoxia can be hypothesized. Indeed, hypoxia is involved in the pathogenesis of several musculoskeletal diseases [45,46] and is able to induce IGFBP-3 via HIF-1α in a wide range of cell cultures [47,48]. It has also been demonstrated that hypoxia increases the expression of HMGA proteins [7].

Conclusions
Collectively, our data indicate that IGFBP-3 expression is increased both in the C-28/I2 chondrocytic cell line and in the chondrocytes of osteoarthritic patients in comparison with T/C-28a4 cell line and healthy human cartilage controls, respectively. Given our observations
that HMGA1 is implicated in the upregulation of IGFBP-3 protein expression, it is tempting to hypothesize that HMGA1 acts as a regulator of articular cartilage homeostasis. Future studies will further clarify the role of HMGA1 in the pathomechanisms of OA.

**Abbreviations**

C/EBPβ: CAAT-enhancer binding protein β; ChIP: chromatin immunoprecipitation; CoX: type X collagen; Ct: cycle threshold; EMSA: electrophoretic mobility shift assay; HMGA1: high-mobility group A1; IGF-I: insulin-like growth factor I; IGFBP-3: insulin-like growth factor binding protein 3; OA: osteoarthritis; PCR: polymerase chain reaction; PGL3-IGFBP-3: Luciferase reporter plasmid; qRT-PCR: quantitative real-time reverse transcription-polymerase chain reaction; RPS9: ribosomal protein S9; siRNA: small interfering RNA.

**Acknowledgements**

We are most grateful to Mary B Goldring (The Hospital for Special Surgery, New York, NY, USA) and Elizaveta Kon (Rizzoli Orthopedic Institute, Bologna, Italy) for providing us with the human chondrocytic cell lines T/C-28A4 and C-28/I2.

**Author details**

1. Department of Orthopedics, Magna Graecia University, V.le Europa, Catanzaro, 88100 Italy. 2. Department of Neuroscience and Brain Technologies, Istituto Italiano di Tecnologia, Via Morego, Genoa, 16163 Italy. 3. Department of Health Sciences, Magna Graecia University, V.le Europa, Catanzaro, 88100 Italy.

**Authors’ contributions**

GG, AB, and OG conceived the study; had full access to all of the data, and wrote the manuscript. MDG, FP, and EC performed most of the experiments. MDG, FP, and EC wrote the manuscript. MDG, FP, and EC performed most of the experiments. GG, AB, and OG conceived the study, had full access to all of the data, and wrote the manuscript. MG, FG, and FG contributed important intellectual content. All authors have read and approved the final manuscript.

**Authors’ information**

GG has an MD and is a full professor of orthopedics and head of the Orthopedics and Traumatology Department, Magna Graecia University and Mater Domini University Hospital (Catanzaro, Italy). MDG has an MD and is a resident in orthopedics and traumatology, Magna Graecia University and Mater Domini University Hospital. PP has a BS and is a researcher at the Department of Neurosciences and Brain Technologies, Istituto Italiano di Tecnologia (Genoa, Italy). EC has an MD and is a researcher at the Department of Health Sciences, Magna Graecia University. AB has an MD and a PhD and is an associate professor of endocrinology, Department of Health Sciences, Magna Graecia University and Mater Domini University Hospital. OG has an MD and is an assistant professor of orthopedics, Department of Orthopedics and Traumatology, Magna Graecia University and Mater Domini University Hospital.

**Competing interests**

The authors declare that they have no competing interests.

**Received:** 5 April 2012  **Revised:** 23 August 2012  **Accepted:** 4 October 2012  **Published:** 4 October 2012

**References**

1. Reeves R: Nuclear functions of the HMGA proteins. Biochim Biophys Acta 2010, 1799:9-14.

2. Bustin M: Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol 1990, 10:5327-5346.

3. Reeves R, Beckerlser L: HMGI(Y) proteins: flexible regulators of transcription and chromatin structure. Biochim Biophys Acta 2001, 1519:13-29.

4. Foti D, Iuliano R, Chefiari E, Brunetti A: A nucleoprotein complex containing Sp1, C/EBPβ, and HMGI-Y controls human insulin receptor gene transcription. Mol Cell Biol 2003, 23:2720-2732.

5. Chefiari E, Nevolo MT, Ardasiconio B, Maurizio E, Nofera A, Intorno S, Sparrà R, Possidione K, Palmieri C, Paonessa F, Brunetti G, Mannirotti G, Foti D, Brunetti A: HMGA1 is a novel downstream target of the insulin receptor signaling pathway. Sci Rep 2012, 2:251.

6. Purohit PK, Nelson PC: Effect of supercooling on formation of protein-mediated DNA loops. Phys Rev E 2006, 74, 061907.

7. Ji YS, Xu Q, Schmiddt JF: Hypoxia induces high-mobility-group protein I (Y) and transcription of the cyclooxygenase-2 gene in human vascular endothelium. Circ Res 1998, 83:295-304.

8. Allander SV, Durham SK, Scheimann AO, Wasserman RM, Suwanichkul A, Powell DR: Hepatic nuclear factor 3 and high mobility group I(Y) proteins bind the insulin response element of the insulin-like growth factor-binding protein-1 promoter. Endocrinology 1997, 138:4291-4300.

9. Rajaram S, Baylink DJ, Mohan S: Insulin-like growth factors-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 1997, 18:801-831.

10. Martin JA, Spretel MB, Lembleke LA, Buckwalter JA: Damage control mechanisms in articular cartilage: the role of the insulin-like growth factor I axis. Iowa Orthop J 2000, 20:1-10.

11. Hantzeri SB, Kapfinger E, Martin J, Buckwalter JA, Morales TI: Insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) is closely associated with the chondrocyte nucleus in human articular cartilage. Osteoarthritis Cartilage 2008, 16:185-194.

12. Martel-Pelletier J, Di Battista JA, Lajeunesse D, Pelletier JP: IGF/I/IGFBP axis in cartilage and bone in osteoarthritis pathogenesis. Arthritis Rheum 1998, 47:90-100.

13. Goldring MB: Cytokines, growth factors, and bone-derived factors in cartilage. In Bone and Osteoarthritis. Edited by: Bronner F, Farach-Carson MC. London: Springer; 2007:41-63.

14. Rengel Y, Ospelt C, Gay S: Proteinases in the joint: clinical relevance of proteinases in joint destruction. Arthritis Res Ther 2007, 9:221.

15. Galasso O, Familiari F, De Goi M, Gasparini G: Recent findings on the role of gelatinases (matrix metalloproteinase-2 and -9) in osteoarthritis. Adv Orthop 2012, 2012, 834208.

16. Iwanaga H, Matsumoto T, Enomoto H, Okano K, Hishikawa Y, Shindo H, Koji T: Enhanced expression of insulin-like growth factor-binding proteins in human osteoarthritic cartilage detected by immunohistochemistry and in situ hybridization. Osteoarthritis Cartilage 2005, 13:439-446.

17. Tardif G, Reboul P, Pelletier JP, Geng C, Cloutier JM, Martel-Pelletier J: Normal expression of type 1 insulin-like growth factor receptor by human osteoarthritic chondrocytes with increased expression and synthesis of insulin-like growth factor binding proteins. Arthritis Rheum 1996, 39:969-976.

18. De Craenick F, Caliez A, Dassin Trou C, Arract P, Renadr P: Pharmacological disruption of insulin-like growth factor 1 binding to IGF-binding proteins restores anabolic responses in human osteoarthritic chondrocytes. Arthritis Res Ther 2004, 6:93-403.

19. Brunetti A, Mannirotti G, Chefiari E, Goldfine ID, Foti D: Transcriptional regulation of human insulin receptor gene by the high-mobility-group proteins HMGI(Y). FASEB J 2001, 15:492-500.

20. Foti D, Chefiari E, Fedele M, Iuliano R, Brunetti L, Paonessa F, Mafioli G, Barbetti F, Brunetti A, Croce CM, Fusco A, Brunetti A: Lack of the architectural factor HMGA1 causes insulin resistance and diabetes in humans and mice. Nat Med 2005, 11:765-773.

21. Paonessa F, Foti D, Costa V, Chefiari E, Brunetti G, Leone F, Luciano F, Wu F, Lee AS, Galliera E, Fusco A, Brunetti A: Activator protein-2 overexpression accounts for increased insulin receptor expression in human breast cancer. Cancer Res 2006, 66:5085-5093.

22. Altman R, Alarcón G, Appelrouth D, Bloch D, Borenstein D, Brandt K, Brown C, Cooke TD, Daniel W, Feldman D, Greenwald R, Hochberg M, Howell D, Ike R, Kapila P, Kaplan D, Koopman W, Lee AS, Lief T, McFarland W, McKinney WA, Osrail T, Ramsey-Goldman R, Rothschild B, Wolfe F: The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991, 34:505-514.

23. Altman R, Aich E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke TD, Greenwald R, Hocking M, Howell D, Kaplan D, Koopman W,
Longley S III, Mankin H, McShane DJ, Medger T Jr, Meenan R, Mikkelsen W, Moskwitz R, Murphy W, Rothschild B, Segal M, Sokoloff L, Wolfe F: Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritides of the knee. *Arthritis Rheum* 1986, 29:1039-1049.

24. Kellogg LH, Jeffrey MR, Ball J: Atlas of standard radiographs of arthritis. In *The Epidemiology of Chronic Rheumatism*. Volume 2. Edited by: Kellogg LH, Jeffrey MR, Ball J. Oxford: Blackwell Scientific Publications; 1963:14-19.

25. Ahlbäck S: Osteoarthrosis of the knee. A radiographic investigation. *Acta Radiol* 1968, 7577-72.

26. van der Kraan PM, van den Berg WB: Chondrocyte hypertrophy and osteoarthritis: role in initiation and progression of cartilage degeneration? *Osteoarthritis Cartilage* 2012, 20:223-232.

27. Girkontaite I, Frischholz S, Lammi P, Wagner K, Swoboda B, Aigner T, von der Mark K: Immunolocalization of type X collagen in normal fetal and adult osteoarthritic cartilage with monoclonal antibodies. *Matrix Biol* 1996, 15:231-238.

28. Fukui N, Ikeda Y, Ohnuki T, Tanaka N, Hikita A, Mitomi H, Mori T, Juji T, Katsuragawa Y, Yamamoto S, Sawabe M, Yamane S, Suzuki R, Sandell LI, Ochi T: Regional differences in chondrocyte metabolism in osteoarthritis: a detailed analysis by laser capture microdissection. *Arthritis Rheum* 2008, 58:154-163.

29. Fukui N, Miyamoto Y, Nakajima M, Ikeda Y, Hikita A, Furukawa H, Mitomi H, Tanaka N, Katsuragawa Y, Yamamoto S, Sawabe M, Juji T, Mori T, Suzuki R, Ikegawa S: Zonal gene expression of chondrocytes in osteoarthritic cartilage. *Arthritis Rheum* 2008, 58:3843-3853.

30. Finger F, Schorle C, Zien A, Gebhard P, Goldring MB, Aigner T: Molecular phenotyping of human chondrocyte cell lines T/C-28a2, T/C-28a4, and C-28/I2. *Arthritis Rheum* 2000, 43:3395-3403.

31. Cartharius K, Frech K, Grote K, Haltmeier M, Klingenhoff A, Frisch M, Bayerlein M, Werner T: MatInspector and beyond: promoter analysis based on transcription factor binding sites. *Bioinformatics* 2005, 21:2933-2942.

32. Morales TI: The insulin-like growth factor binding proteins in uncultured human cartilage. Increases in insulin-like growth factor binding protein 3 during osteoarthritis. *Arthritis Rheum* 2002, 46:2359-2367.

33. Morales TI: The quantitative and functional relation between insulin-like growth factor-I and IGF-binding proteins during human osteoarthritis. *Int J Immunopathol Pharmacol* 2003, S24:51-55.

34. Brocher J, Vogel B, Hock R: HMGA1 down-regulation is crucial for chondrocyte hypertrophy and apoptosis at the cartilage-bone interface. *Arthritis Research & Therapy* 2012, 14:R207.

35. Brocher J, Vogel B, Hock R: HMGA1 down-regulation is crucial for chondrocyte hypertrophy and apoptosis at the cartilage-bone interface. *Arthritis Research & Therapy* 2012, 14:R207.

36. Brunetti A, Foti D, Goldfine ID: Regulatory functions of insulin-like growth factor binding proteins in osteoarthritis. *Int J Immunopathol Pharmacol* 2011, 24:51-55.

37. Brocher J, Vogel B, Hock R: HMGA1 down-regulation is crucial for chromatin composition and a gene expression profile permitting myogenic differentiation. *BMC Cell Biol* 2010, 11:64.

38. Brunetti A, Goldfine ID: Role of myogenin in myoblast differentiation and its regulation by fibroblast growth factor. *J Biol Chem* 1990, 265:5960-5963.

39. Brunetti A, Foti D, Goldfine ID: Identification of unique nuclear regulatory proteins for the insulin receptor gene, which appear during myocyte and adipocyte differentiation. *J Clin Invest* 1993, 92:1288-1295.

40. Goldring MB: The role of chondrocyte in osteoarthritis. *Arthritis Rheum* 2000, 43:1961-1926.

41. Aigner T, Kim HA, Roach HI: Apoptosis and osteoarthritis. *Rheum Dis Clin North Am* 2004, 30:639-653.

42. Roach HI, Aigner T, Kouri JB: Chondrocyte: a variant of apoptotic cell death in chondrocytes? *Apoptosis* 2004, 9:265-277.

43. Shapiro IM, Adams CS, Sinivas V, Freeman TA: Chondrocyte hypertrophy and apoptosis at the cartilage-bone interface. In *Bone and Osteoarthritis*. Edited by: Bronner F, Farach-Carson MC. London: Springer; 2007:109-129.

44. Tavera C, Aribat T, Reboul P, Dore S, Brazeau P, Pelletier JP: IGF and IGF binding protein systems in synovial fluid of osteoarritic and inflammatory synovial fluid. *J Rheumatol* 1996, 23:815-818.

45. Konisti S, Kinaidis S, Paleolog EM: Hypoxia. A key regulator of angiogenesis and inflammation in rheumatoid arthritis. *Nat Rev Rheumatol* 2012, 8:153-162.

46. Donato G, Galasso O, Valentino P, Conforti F, Zuccalà V, Russo E, Maltese L, Ferrotta I, Tripepi S, Amorosi A: Pathological findings in subsynovial connective tissue in idiopathic carpal tunnel syndrome. *Clin Neuropathol* 2009, 28:129-135.

47. Zappalà G, Rechler MM: IGFBP-3, hypoxia and TNF-alpha inhibit adiponectin transcription. *Biochem Biophys Res Commun* 2009, 382:785-789.

48. Natsuzaka M, Naganuma S, Kagawa S, Ohashi S, Ashadi A, Subramanian H, Chang S, Nakagawa KJ, Ji X, Liebhaber SA, Klein-Szanto AJ, Nakagawa H: Hypoxia induces IGFBP3 in esophageal squamous cancer cells through HIF-1α-mediated mRNA transcription and continuous protein synthesis. *FASEB J* 2012, 26:2620-2630.

Submit your manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, Caspocs and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit